Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays

Adams CP, Brantner VV. Estimating the cost of new drug development: Is it really $802 million? Health Affair. 2006;25(2):420–8.

Allen DD, Caviedes R, Càrdenas AM, Shimahara T, Segura-Aguilar J, Caviedes PA. Cell lines as in vitro models for drug screening and toxicity studies. Drug Dev Ind Pharm. 2005;31:757–68.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.

Lü L, Zhang L, Wai MSM, Yew DTW, Xu J. Exocytosis of MTT formazan could exacerbate cell injury. Toxicol in Vitro. 2012;26:636–44.

Stockert JC, Blázquez-Casto A, Cañete M, Horobin RW, Villanueva A. MTT assay for cell viability: intracellular localisation of the formazan product is in lipid droplets. Acta Histochem. 2012;114:785–96.

Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989;119(2):203–10.

Van Rensburg CEJ, Anderson R, Jooné G, Myer MS, O’Sullivan JF. Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multi drug resistant cancer cell line. Anti-Cancer Drug. 1997;8:708–13.

Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;8(48):4827–33.

Khabar KSA, Al-Zoghaibi F, Dzimiri M, Taha M, Al-Tuwaijri A, Al-Ahdal MN. MTS Interferon Assay: A simplified cellular dehydrogenase assay for interferon activity using a water-soluble tetrazolium salt. J Interf Cytok Res. 1996;16:31–3.

Peskin AV, Winterbourn CC. A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin Chim Acta. 2000;293:157–66.

Ganapathy-Kanniappan S, Morgan RH. The pyruvic acid analogue 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. Assay Drug Dev Techn. 2010;8(2):258–62.

Brugisser R, Von Daeniken K, Jundt G, Schaffner W, Tullberg-Reinert H. Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med. 2002;68:445–8.

Wang X, Ge J, Wang K, Qian J, Zou Y. Evaluation of MTT Assay for Measurement of Emodin-Induced Cytotoxicity. Assay Drug Dev Technol. 2006;4(2):203–7.

Wang P, Henning SM, Heber D. Limitations of MTT and MTS-based assays for measurements of antiproliferative activity of green tea polyphenols. PLoS One. 2006;5(4):1–10.

Wang S, Yu H, Wickliffe JK. Limitation of the MTT and XTT assays for measuring cell viability due to superoxide formation induced by nano-scale TiO2. Toxicol In Vitro. 2011;25:2147–51.

Fischer J, Prosenc MH, Wolff M, Hort N, Willumeit R, Feyerabend F. Interference of magnesium corrosion with tetrazolium-based cytotoxicity assays. Acta Biomater. 2010;6:1813–23.

Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 1991;51:2515–20.

Gonzalez RJ, Tarloff JB. Evaluation of hepatic subcellular fractions for alamar blue and MTT reductase activity. Toxicol In Vitro. 2001;15:257–9.

Zhang SZ, Lipsky MM, Trump BF, Hsu IC. Neutral red (NR) assay for cell viability and xenobiotic-induced cytotoxicity in primary cultures of human and rat hepatocytes. Cell Biol Toxicol. 1990;6(2):219–34.

Goegan P, Johnson G, Vincent R. Effects of serum protein and colloid on the Alamar Blue assay in cell cultures. Toxicol In Vitro. 1995;9(3):257–66.

Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, et al. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumour cell lines. J Natl Cancer Inst. 1990;82:1113–8.

Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112–6.

National Cancer Institute Screening Services. NCI-60 DTP Human Tumor Cell Line Screen. http://www.cancer.gov (2014). Accessed 5 January 2015.

Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39:1358–66.

Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei III E. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol. 1989;25:32–6.

Warburg O, Posener K, Negelein E. Uber den stoffwechsel der tumoren. Biochem Z. 1924;152:319–44.

Kim J-W, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66(18):8927–30.

Pelicano H, Martin DS, Xu R-H, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–46.

Borenfreund E, Puerner JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett. 1985;24(2–3):119–24.

Fotakis G, Timbrell JA. In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett. 2006;160:171–7.

Repetto G, Del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc. 2008;3(7):1125–31.

McMillian MK, Li L, Parker JB, Patel L, Zhong Z, Gunnett JW, et al. An improved resazurin-based cytotoxicity assay for hepatic cells. Cell Biol Toxicol. 2002;18:157–73.

Jabbar SAB, Twentyman PR, Watson JV. The MTT assay underestimates the growth inhibitory effects of interferons. Br J Cancer. 1989;60:523–8.

Hamid R, Rotshteyn Y, Rabadi L, Parik H, Bullock P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro. 2004;18:703–10.

Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod. 2007;22(5):1304–9.

Hayon T, Dvilansky A, Shpilberg O, Nathan I. Appraisal of the MTT-based assay as useful tool for predicting drug chemosensitivity in leukaemia. Leukaemia Lymphoma. 2003;44(11):1957–62.

Sieuwert AM, Klijn JG, Peters HA, Foekens JA. The MTT tetrazolium salt assay scrutinised: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50 values and cell survival. Eur J Clin Chem Biochem. 1995;33:813–23.

Keepers YR, Pizao PE, Peters GJ, Van Ark-Otte J, Winograd B, Pinedo HM. Comparison of the Sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer. 1991;27(7):897–900.

Queirόs O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, et al. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumour activity of 3-bromopyruvate. J Bioenerg Biomembr. 2012;44:141–53.

Zhang F, Aft RL. Chemosensitising and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells. J Cancer Res Ther. 2009;1(5):S41–3.